Educational guide
P21 (P021; Ac-DGGLAG-NH2) — The Complete History
The Crisis Loss and Legacy 2012–Present: Continuing Without Her Key Moment Inge Grundke-Iqbal's death in 2012 marked both an ending and a challenge: the loss of a pioneer, and the difficulty of translating brilliant preclinical science into human therapies. In
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
The Crisis
Loss and Legacy
2012–Present: Continuing Without Her
Key Moment
Inge Grundke-Iqbal's death in 2012 marked both an ending and a challenge: the loss of a pioneer, and the difficulty of translating brilliant preclinical science into human therapies.
In 2012, tragedy struck the laboratory on Staten Island. Dr. Inge Grundke-Iqbal, the visionary who had asked the question that led to P21, passed away. She was seventy-five years old. She never saw P21 tested in human patients. She never knew if the peptide that emerged from her scientific curiosity would eventually heal Alzheimer's disease in people. Her death marked a turning point: the loss of a scientific giant, and the challenge of continuing her work without her.
Khalid Iqbal carried on, supported by colleagues like Narjes Baazaoui and others at the Institute. The preclinical evidence continued to grow. Yet translating P21 from mouse models to human trials remained a formidable challenge. The regulatory pathway for peptide therapeutics is complex. Funding for early-stage neurodegeneration research is scarce. Pharmaceutical companies prefer larger molecules that can be patented and protected. A four-amino-acid peptide, elegant though it is, does not fit the usual business model of drug development. Nevertheless, the work proceeded steadily in the shadows of academic research—published, peer-reviewed, but not yet reaching the clinic.
P21 also found application beyond Alzheimer's disease. Researchers tested it in models of CDKL5 deficiency disorder, a severe developmental epilepsy. The peptide's ability to promote neurogenesis and enhance synaptic plasticity suggested potential benefit in any condition where neuronal survival and connection are compromised. Yet without a corporate sponsor, without the machinery of clinical trials, P21 remained in the preclinical realm—powerful in the laboratory, promising on paper, but not yet available to patients. The greatest challenge was not scientific; it was translational. How do you bring a academic discovery into clinical practice?